Nature Reviews Cardiology - Table of Contents alert Volume 11 Issue 11

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
November 2014 Volume 11 Number 11
Impact Factor 10.154 *	In this issue Editorial Research Highlights Focus on: 10th anniversary Perspectives Correspondence Reviews Also this month  Web focus: 10th anniversary
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Nature has once again been ranked the N0.1 weekly science journal with an Impact Factor of 42.351*. Subscribe to Nature for only $42, £42 or €42. You will receive print, online and app access, providing unbelievable value for money. This is a limited time offer - so don't miss out and subscribe today!   *2013 Journal Citation Reports® (Thomson Reuters, 2014)
EDITORIAL		Top
Celebrating the first 10 years of Nature Reviews Cardiology Gregory B. Lim p617 | doi:10.1038/nrcardio.2014.158 Full Text | PDF
RESEARCH HIGHLIGHTS Top Heart failure: LCZ696—a PARADIGM shift in treatment for heart failure Published online: 16 September 2014 p618 | doi:10.1038/nrcardio.2014.139 PDF Coronary artery disease: Fractional flow reserve-guided management of CAD Published online: 16 September 2014 p619 | doi:10.1038/nrcardio.2014.140 PDF Anticoagulant therapy: Rivaroxaban for patients with AF undergoing cardioversion Published online: 16 September 2014 p620 | doi:10.1038/nrcardio.2014.151 PDF Interventional cardiology: Colchicine therapy prevents postpericardiotomy syndrome but not postoperative atrial fibrillation Published online: 16 September 2014 p620 | doi:10.1038/nrcardio.2014.152 PDF Acute coronary syndromes: Risk of major coronary events not reduced by darapladib therapy Published online: 16 September 2014 p621 | doi:10.1038/nrcardio.2014.148 PDF Coronary artery disease: Stable CAD does not SIGNIFY ivabradine therapy Published online: 16 September 2014 p621 | doi:10.1038/nrcardio.2014.149 PDF Heart failure: Vagal stimulation in patients with HF Published online: 16 September 2014 p621 | doi:10.1038/nrcardio.2014.150 PDF Heart failure: Long-term iron therapy is beneficial in patients with HF Published online: 16 September 2014 p622 | doi:10.1038/nrcardio.2014.147 PDF Atherosclerosis: Regression of coronary atherosclerosis with statin therapy Published online: 23 September 2014 p623 | doi:10.1038/nrcardio.2014.154 PDF Arrhythmias: Amiodarone fails to lower AF recurrence in AMIO-CAT trial Published online: 23 September 2014 p623 | doi:10.1038/nrcardio.2014.155 PDF IN BRIEF Antiplatelet therapy: Prehospital administration of ticagrelor in patients with STEMI is safe, but does not improve reperfusion | Interventional cardiology: New ultrathin, biodegradable-polymer stent noninferior to existing durable-polymer model | Hypertension: Blood-pressure lowering most beneficial in patients at highest cardiovascular risk | Acute coronary syndromes: Routine thrombus aspiration before PCI in patients with STEMI not to TASTE | Pericarditis: Neither glucocorticoid therapy nor immunotherapy improves outcomes in patients with tuberculous pericarditis | Acute coronary syndromes: Pharmacotherapy to limit reperfusion injury after STEMI fails to reduce infarct size PDF Cardiology JOBS of the week Postdoctoral Scholar for the Study of the Molecular Basis of Cardiac Development and Congenital Heart Disease University of Chicago Post-doctoral Fellow University Health Network Research Associate East Tennessee State University, Quillen College of Medicine More Science jobs from Cardiology EVENT Asian Pacific Society of Cardiology Congress 2015 29.04.15 Abu Dhabi, UAE More science events from
NEWS AND VIEWS		Top
Decade in review—acute coronary syndromes: Successes and future objectives in acute coronary syndrome Frans Van de Werf Published online: 02 September 2014 p624 | doi:10.1038/nrcardio.2014.129 The past decade has seen considerable advances in the treatment of acute coronary syndromes (ACS), particularly in the search for improved antithrombotic therapies. Despite these successes, however, renewed efforts are needed to improve long-term outcomes after ACS by reducing recurrent ischaemic events and lowering the risk of bleeding complications. Full Text | PDF
Decade in review—arrhythmias: Cardiac fibrillation—challenges and evolving solutions Stanley Nattel Published online: 09 September 2014 p626 | doi:10.1038/nrcardio.2014.133 Cardiac rhythm disorders, or 'arrhythmias', are major sources of morbidity and mortality, and have been challenging to treat because classic pharmacological therapies are often ineffective and sometimes dangerous. In the past decade, groundbreaking developments have revolutionized the management of arrhythmias and prepared the groundwork for new advances in the future. Full Text | PDF
Decade in review—cardiomyopathies: Cardiomyopathy on the move Magdi H. Yacoub Published online: 30 September 2014 p628 | doi:10.1038/nrcardio.2014.157 Since Wallace Brigden first used the term 'cardiomyopathy' in 1952, this group of diseases has continued to attract the interest of clinicians, researchers, and importantly, patients. The past decade has seen a substantial accumulation of knowledge relating to various cardiomyopathies, which has partially lifted the mystery surrounding this topic. Full Text | PDF
Decade in review—dyslipidaemia: Resurgence of targets and compounds to treat dyslipidaemia John J. P. Kastelein Published online: 09 September 2014 p629 | doi:10.1038/nrcardio.2014.132 Over the past decade, we have witnessed the unparalleled success of statins to treat dyslipidaemia. Target identification by Mendelian randomization, human monoclonal antibodies, gene therapy, RNA-based targets, and atherogenic lipoproteins other than LDL cholesterol have fuelled intense development efforts that might bear fruit in the very near future. Full Text | PDF
Decade in review—heart failure: 10 Years of progress in HF research—what have we learned? Henry Krum Published online: 02 September 2014 p631 | doi:10.1038/nrcardio.2014.127 In this Decade in Review article, I highlight the top 10 advances in heart failure (HF) over the past decade, including new pharmacological therapies and expanded indications for devices in HF with reduced ejection fraction. The poor progress in acute HF and HF with preserved ejection fraction is emphasised. Biomarkers and devices that help prevent, detect, and guide treatment represent the future of HF management. Full Text | PDF
Decade in review—hypertension: The past decade in hypertension—facts, hopes, and hypes Thomas Unger Published online: 02 September 2014 p633 | doi:10.1038/nrcardio.2014.131 Hypertension research in the past decade has been a mixture of hope and hype. In the absence of new drug developments, clinical intervention procedures such as renal nerve ablation and baroreflex activation therapy have dominated the research, but the results have not yet fulfilled the great expectations. Full Text | PDF
Decade in review—peripheral vascular disease: 10 Years of breakthroughs in peripheral vascular disease Mark A. Creager Published online: 30 September 2014 p635 | doi:10.1038/nrcardio.2014.153 Clinical trials published during the past decade have had substantial effects on the treatment of peripheral vascular diseases. In this article, I discuss ten important trials that have influenced treatment for common vascular disorders, including peripheral artery disease, abdominal aortic aneurysm, renal artery disease, extracranial carotid artery disease, and venous thromboembolism. Full Text | PDF
Decade in review—valvular disease: Current perspectives on treatment of valvular heart disease Friedrich W. Mohr Published online: 23 September 2014 p637 | doi:10.1038/nrcardio.2014.138 Tremendous advances in the understanding and treatment of structural heart valve disease have been made in the past decade, including widespread utilization of minimally-invasive surgical procedures and the invention and evolution of numerous interventional techniques. These innovations will become the norm in therapy for valvular disease in the future. Full Text | PDF
Focus on: 10th anniversary PERSPECTIVES Top VIEWPOINT Exploring unknowns in cardiology Ottavio Alfieri, Bongani M. Mayosi, Seung-Jung Park, Nizal Sarrafzadegan & Renu Virmani Published online: 23 September 2014 p664 | doi:10.1038/nrcardio.2014.123 To mark the 10th anniversary of Nature Reviews Cardiology, five of our Advisory Board members were invited to consider a topic within cardiology about which we know too little. The key opinion leaders from around the globe also suggest ways in which future research could be targeted to address the deficits in our understanding, with the aim of preventing cardiovascular disease, improving patient care, and reducing morbidity and mortality. Abstract | Full Text | PDF OPINION Top 10 cardiovascular therapies and interventions for the next decade Valentin Fuster Published online: 30 September 2014 p671 | doi:10.1038/nrcardio.2014.137 The global epidemic of cardiovascular disease is being fuelled by the spread of a Western lifestyle characterized by a high prevalence of cardiovascular risk factors. In this Perspectives article, Valentin Fuster highlights 10 therapies and interventions that, in his opinion, will be most useful in combating cardiovascular disease and promoting cardiovascular health over the next decade. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Capabilities, limitations, and misconceptions of using OCT to assess vulnerable plaques Mark E. Brezinski Published online: 23 September 2014 p638 | doi:10.1038/nrcardio.2014.62-c1 Full Text | PDF
REPLY		Top
Matching human pathology is essential for validating OCT imaging to detect high-risk plaques Renu Virmani, Fumiyuki Otsuka, Francesco Prati, Jagat Narula & Michael Joner Published online: 23 September 2014 p638 | doi:10.1038/nrcardio.2014.62-c2 Full Text | PDF
CORRESPONDENCE		Top
Ethnicity and sympathetic tone: predictors of the blood pressure response to renal denervation? Yutang Wang Published online: 30 September 2014 p638 | doi:10.1038/nrcardio.2014.70-c1 Full Text | PDF
REPLY		Top
Renal denervation—a valid treatment option despite SYMPLICITY HTN-3 Roland E. Schmieder Published online: 30 September 2014 p638 | doi:10.1038/nrcardio.2014.70-c2 Full Text | PDF
REVIEWS		Top
Global epidemiology of atrial fibrillation Faisal Rahman, Gene F. Kwan & Emelia J. Benjamin Published online: 12 August 2014 p639 | doi:10.1038/nrcardio.2014.118 The prevalence of atrial fibrillation (AF) is estimated to increase worldwide, mainly as a consequence of generalized population ageing. Even though the rise in AF prevalence is a global trend, data from Africa, Asia, and South America are limited and might underestimate the true frequency of AF. In this Review, the authors discuss the available epidemiological data on AF and highlight the widespread inadequacy of its treatment. Abstract | Full Text | PDF
Noncoding RNAs and myocardial fibrosis Thomas Thum Published online: 09 September 2014 p655 | doi:10.1038/nrcardio.2014.125 During stress or injury-induced cardiac remodelling, fibroblasts increase production of extracellular matrix proteins, which leads to fibrosis formation, and consequently, heart failure. In this Review, Thomas Thum describes the contribution of noncoding RNAs to this process, with a specific focus on microRNAs that might be used as future therapeutic targets or biomarkers for cardiac fibrosis. Abstract | Full Text | PDF
Advertisement
MARKETPLACE: Great deals on the latest lab equipment   New Lab Offers and Product Focus are in!   VISIT MARKETPLACE TODAY
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2013. Nature Reviews Cardiology was previously published as Nature Clinical Practice Cardiovascular Medicine.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.